TC
GBT

TFS Capital’s Global Blood Therapeutics, Inc. GBT Stock Holding History

TFS Capital’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-16,274
Closed -$375K – 935
2016
Q3 		$375K Buy
+16,274
New +$310K 0.09% 365
2016
Q2 		– Sell
-40,343
Closed -$640K – 1240
2016
Q1 		$640K Buy
+40,343
New +$717K 0.09% 378

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

TFS Capital's GBT Position: Q4 2016 in Review

TFS Capital sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2016, closing a stake of 16,274 shares — an estimated $375K sold.

TFS Capital first reported a position in GBT in Q1 2016 and held it in 2 quarters. The position peaked at $640K in Q1 2016. 96 funds tracked by Wall St. Rank hold GBT as of Q4 2016.

  • TFS Capital reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
  • TFS Capital sold 16,274 Global Blood Therapeutics, Inc. shares in Q4 2016, an estimated $375K.
  • TFS Capital first reported a position in Global Blood Therapeutics, Inc. in Q1 2016 and held it in 2 quarters.
  • TFS Capital's Global Blood Therapeutics, Inc. position peaked at $640K in Q1 2016.
  • 96 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2016.

Based on TFS Capital's 13F filing for Q4 2016, filed 20 Jan 2017.